Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

NCT04988386 is registered in ClinicalTrials.gov with Eidos Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT04988386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04988386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 27, 2021
Completion date
May 15, 2028
Enrollment
389 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid cardiomyopathy, transthyretin-related